Iva is part of the Evotec BRIDGEs North America team, including LAB150. Prior to joining Evotec, Iva spent 6 years in Biopharma strategy consulting enabling clients to develop strategic insights and decisions pertaining to new product development, portfolio prioritization, clinical development, commercial opportunity assessments, as well as due diligence for buy-side and sell-side opportunities. Previously, she was a founding employee at Alnylam Pharmaceuticals, the leader in RNAi therapeutics. During her 9 year tenure at Alnylam, as part of a multi-disciplinary team she advanced several programs to clinic, most notably ALN-RSV (a virology program) and ALN-VSP (an oncology program). She led the initiation of two hematology programs ALN-AT3 for the treatment of hemophilia (currently in clinic) and ALN-TMP for the treatment of beta-thalassemia.
Iva earned a Doctor of Philosophy from Bulgarian Academy of Sciences in Molecular Genetics and Masters of Business Administration from F.W. Olin Graduate School of Business at Babson College.